Entities / Company
MediWound (Germany).
company in Rüsselsheim, Germany
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
MediWound's ownership structure as of July 7, 2025, includes Clal Life Sciences L.P. as the largest shareholder, alongside Mölnlycke Health Care AB and Investor AB.Speculative1 report
-
MediWound announced multiple clinical partnerships on August 14, 2025, including collaborations with Kerecis, MiMedx, Convatec, and Essity.Some support1 report1 development inside
-
MediWound announced findings from its clinical trial conducted in Yavne.Some support1 report
-
MediWound (Germany) operates within the Medical Drugs Industry and was noted to have underperformed the S&P 500 this year.Some support1 report
-
MediWound (Germany) announced on August 15, 2025, that its revenue growth forecast is higher than the industry average.Some support1 report
-
MediWound received FDA approval for its biologic NexoBrid and announced its corporate structure and market presence.Some support3 reports
-
MediWound and NexoBrid participated in the EBA Congress, which was held in Berlin, Germany, in September 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around MediWound (Germany) this week
News at the entities that move MediWound (Germany) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves MediWound (Germany)
-
LinkedIn OperationalBoth LinkedIn and Google are currently being utilized as platforms for news distribution.Moves MediWound (Germany)
Connections
The 6 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates MediWound through protocol submissions, inspections, and product approvals.
-
Daniel Ferry Structural
Daniel Ferry serves as the CFO for MediWound.
-
Kerecis Operational
Kerecis and MediWound actively collaborate on clinical trials and research programs.
-
LinkedIn Operational
MediWound uses LinkedIn as a platform for corporate updates and professional presence.
-
MiMedx Operational
MediWound and MiMedx are collaborating and supporting each other in clinical trials.
-
Yavne Shared context
MediWound operates and conducts clinical trials within the geographical context of Yavne.
History
Events by the month they beganJune 2026
7 events- MediWound's ownership structure as of July 7, 2025, includes Clal Life Sciences L.P. as the largest shareholder, alongside Mölnlycke Health Care AB and Investor AB.
- MediWound announced multiple clinical partnerships on August 14, 2025, including collaborations with Kerecis, MiMedx, Convatec, and Essity.
- MediWound announced findings from its clinical trial conducted in Yavne.
- MediWound (Germany) operates within the Medical Drugs Industry and was noted to have underperformed the S&P 500 this year.
- MediWound (Germany) announced on August 15, 2025, that its revenue growth forecast is higher than the industry average.
- MediWound received FDA approval for its biologic NexoBrid and announced its corporate structure and market presence.
- MediWound and NexoBrid participated in the EBA Congress, which was held in Berlin, Germany, in September 2025.